InnoCan Pharma Corporation (CSE:INNO)
Canada flag Canada · Delayed Price · Currency is CAD
6.24
+0.24 (4.00%)
Apr 28, 2026, 12:06 PM EST

InnoCan Pharma Company Description

InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally.

The company operates through two segments: Pharmaceuticals and Consumer Wellness. The company's Pharmaceutical segment engages in the development of drug delivery technologies for both human and animal health applications, based on advanced cannabinoids science.

It offers a Cannabidiol-loaded Liposome injection Platform (LPT-CBD) that facilitates dosing and release of synthetic cannabidiol into the blood stream for the treatment of chronic pain.

The company's Consumer Wellness segment engages in the development and marketing of self-care and hemp-derived cannabidiol beauty products through the brand B.I.

Sky. Skincare and Beauty: Its skincare product range includes face creams, serums, masks, soaps, and neck creams for the treatment of dark spot, skin discoloration, hyperpigmentation, and anti-aging .

Its pain relief products includes cannabidiol-based topical treatments, such as pain relief sprays and roll-on formulations.

InnoCan Pharma Corporation was founded in 2017 and is headquartered in Calgary, Canada.

InnoCan Pharma Corporation
Country Canada
Founded 2017
Industry Household & Personal Products
Sector Consumer Staples
CEO Iris Bincovich

Contact Details

Address:
1015, 926 – 5 Avenue SW
Calgary, AB T2P 0N7
Canada
Phone 516 210 4025
Website innocanpharma.com

Stock Details

Ticker Symbol INNO
Exchange Canadian Securities Exchange
Fiscal Year January - December
Reporting Currency USD
ISIN Number CA45783P1027
SIC Code 2834

Key Executives

Name Position
Roni Kamhi Chief Operating Officer, Chief Executive Officer of B.I. Sky Global LTD and Director
Iris Bincovich Chief Executive Officer and Interim Chairwoman
Nelson Harvey Halpern F.C.A., FCPA Chief Financial Officer
Eyal Flom L.L.M., M.B.A. Company Secretary, General Counsel and Director
Dr. Eyal Kalo Vice President of Research and Development